Noninvasive Lung Monitoring Device Cuts Heart Failure Deaths and Hospitalizations by Over Seventy Percent

ACC.26 trial shows lung impedance monitoring with CardioSet reduces hospitalizations and deaths by 74% in HFpEF patients through early fluid detection.

By: AXL Media

Published: Mar 30, 2026, 4:02 AM EDT

Source: Information for this report was sourced from American College of Cardiology

A Preventative Breakthrough in Congestion Management for Heart Patients

The landscape of heart failure treatment is shifting toward early, preclinical intervention through the use of highly sensitive monitoring technology. According to Michael Kleiner-Shochat, head of the heart failure clinic at Hillel Yaffe Institute of Cardiology, a noninvasive device that tracks fluid in the lungs has proven remarkably effective for patients with heart failure with preserved ejection fraction, or HFpEF. This specific condition, characterized by a heart muscle that is too stiff to fill properly, often leads to a gradual and dangerous accumulation of fluid known as lung congestion. The new data suggests that by identifying this buildup before physical symptoms even appear, clinicians can intervene with a level of precision that was previously unattainable through standard physical examinations.

Overcoming Technical Barriers in Noninvasive Impedance Monitoring

The core technology behind this advancement relies on measuring electrical resistance, or impedance, within the chest cavity. As fluid builds up in the lungs, they become less resistant to electrical currents, causing impedance levels to drop. While this concept has been explored before, earlier noninvasive devices struggled with "noise" generated by the surrounding chest wall, which often masked subtle changes in lung fluid. The CardioSet device addresses this limitation by utilizing a complex configuration of multiple electrodes that calculate and filter out chest wall interference. This refined accuracy allows medical teams to detect even minute shifts in fluid status, providing a reliable early warning system that functions at every point of care.

Analyzing the Dramatic Drop in Recurrent Hospitalizations

The randomized clinical trial followed 150 patients for over three years, comparing those receiving impedance-guided care against a standard-care control group. The results were statistically staggering, showing only 19 hospitalization events in the guided group compared to 93 in the standard arm. This 74% reduction in recurring hospital visits is attributed to the fact that physicians were able to fine-tune diuretic dosages significantly earlier in the congestion cycle. Furthermore, the average time to a patient's first hospitalization was extended from just 83 days in the standard group to over 600 days for...